Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2003

View Archived Issues

Abraxane exceeds primary efficacy objective in phase III trial

Aripiprazole in schizophrenia and bipolar disorder

Treatment completed in phase IIb trial of MBI-594AN for acne

Positive phase I results for Cytovaxine

Biogen licenses rights to oral psoriasis product from Fumapharm

FDA approves Zomig nasal spray

BCY LifeSciences completes treatment in phase II DCF-987 trial

VaxGen awarded anthrax vaccine development contract by NIAID

Atomoxetine hydrochloride in children and adults with ADHD

Lack of synergy described for alendronate and PTH in osteoporosis

Novel NPY Y5 antagonists prepared and tested at Roche

Recent patents cover new 5-HT6 modulators for psychosis, other CNS disorders and imaging

New antibacterial oxazolidinones discovered at P&U (now Pfizer)

Bayer presents two novel series of antitumor agents in recent patent literature

Schering presents new contrast agents for X-ray and NMR

Novel PI3-kinase inhibitors and their use described by Novartis scientists

Abbott seeks approval for Humira for improvement of physical function in RA

Rolling NDA submission continues for RSR-13

Arius and PDL enter cancer antibody development partnership

Medarex and Trillium collaborate on development of antibody therapeutics

Preclinical update provided for ENT-103

Neuprex tested for potential in pediatric open heart surgery

Forest discontinues development of dexloxiglumide for constipation-predominant IBS

Potential new amyloid-imaging agent presented to Japanese Society of Dementia

Anti-HIV candidate with unique resistance profile and promising pharmacokinetics

Inhaled ilomastat prevents cigarette smoke-induced lung damage in mouse model of emphysema

Novel antibacterial agents targeting enoyl-ACP reductase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...